-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
Targeted Therapies
-
Research to Watch: Aumolertinib Delivers Notable Performance as an EGFR-Targeted Therapy in the Adjuvant Setting
Results from the phase III ARTS trial illustrate the potential of aumolertinib as adjuvant therapy for patients with resected EGFR-mutated NSCLC.
-
The Power of Team-Based Science
After being awarded the $2.5 million IASLC-LCRF grant, ILCN follows up with the research progress of Dr. David Barbie and his international team of investigators.
-
Targeting NRG1 Fusions: A Potential Role for Zenocutuzumab as a First-Line Therapeutic Option
Dr. Stephen Liu recently highlighted the safety and efficacy of a targeted therapy for patients with NRG1-positive cancers with updated data from the ongoing eNRGy trial.
-
Tarlatamab With Anti-PD-L1 Demonstrates OS Benefit as First-Line Maintenance Therapy After Chemo-IO in ES-SCLC
Lead investigator Dr. Kelly Paulson said the combination demonstrated unprecedented overall survival with a manageable safety profile in this patient population.
-
Early Data Suggest Primary Tumor Resection Following EGFR TKI Treatment May Help Delay Disease Progression in Metastatic NSCLC
PTR-1 trial results, recently presented by Dr. Pei-Hsing Chen, showed a higher pathological complete response for exon 19 deletions and greater survival benefit from the intervention for L858R mutations.
-
Patient Comment on Mobocertinib for Exon 20
Mobocertinib for Exon 20-Related Lung Cancer of Great Interest to Patients My brother Kevin, who founded the Exon 20 Group at ICAN with me in early 2017, started on mobocertinib (TAK-788) in late Spring of 2017. It was Kevin’s first clinical trial, and he was very pleased to be under the care of study leader…
-
Trastuzumab Deruxtecan Potential New Treatment Options for HER2+ NSCLC
The novel antibody drug conjugate trastuzumab deruxtecan (T-DXd) demonstrated clinically meaningful and promising efficacy in patients with HER2-mutated NSCLC, according to interim results of the DESTINY-Lung01 trial, presented as part of the mini oral session, “MA11: Expanding Targetable Genetic Alerations in NSCLC.” “These data demonstrate the potential of T-DXd as a new treatment option in…
-
Targeting KRAS in Lung Cancer: The Past, Present, and Future
Although RAS mutations constitute some of the most common genetic alterations in patients with adenocarcinomas, efforts to target the RAS oncoprotein have not proven fruitful, not only in NSCLC but across all cancers. In fact, researchers have been searching for an effective RAS inhibitor for more than 3 decades, leading many to believe that RAS…
-
Mobocertinib May Offer Effective, Safe Treatment in NSCLC with EGFR Exon 20 Insertion Mutation
With no approved treatments for advanced NSCLC with EGFR exon 20 insertion mutations, treatment is mainly limited to chemotherapy, as these cancers don’t respond to traditional tyrosine kinase inhibitors (TKIs). But previously treated patients with this rare subtype responded to mobocertinib, with a manageable safety profile, in a phase I/II trial discussed during (OA04: New…
View ILCN Archives
Provider Resources
Popular Articles